SCHEMBL29490334

SCHEMBL29490334

Cn1c(=O)n(C)c2cc(Cn3cnc4cccc(Br)c43)ccc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 5/20 0.45
▸ HTT P42858 4/20 0.45
▸ UBE2N P61088 2/20 0.45
▸ L3MBTL1 Q9Y468 2/20 0.45
▸ GLA P06280 1/20 0.45
▸ RXFP1 Q9HBX9 2/20 0.43
▸ TP53 P04637 1/20 0.43
▸ LMNA P02545 4/20 0.43
▸ PDE2A O00408 1/20 0.42
▸ PDE1A P54750 1/20 0.42
▸ PDE1B Q01064 1/20 0.42
▸ PDE1C Q14123 1/20 0.42
▸ ADORA2B P29275 1/20 0.42
▸ NR1I2 O75469 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ CYP11B1 P15538 4/20 0.41
▸ CYP11B2 P19099 4/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ ABCC8 Q09428 1/20 0.40
▸ KCNJ11 Q14654 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22862663 0.82 PDE2A (0.42) SMN1; SMN2HTTUBE2NL3MBTL1GLA
SCHEMBL29490209 0.82 PDE2A (0.42) SMN1; SMN2HTTUBE2NL3MBTL1GLA
SCHEMBL29490240 0.82 SMN1; SMN2 (0.42) SMN1; SMN2HTTUBE2NL3MBTL1GLA
SCHEMBL22862448 0.82 SMN1; SMN2 (0.42) SMN1; SMN2HTTUBE2NL3MBTL1GLA
SCHEMBL22862709 0.80 BRD4 (0.45) SMN1; SMN2HTTUBE2NL3MBTL1LMNA
SCHEMBL29490198 0.80 BRD4 (0.45) SMN1; SMN2HTTUBE2NL3MBTL1LMNA
SCHEMBL29490219 0.79 BRD4 (0.46) SMN1; SMN2HTTUBE2NL3MBTL1LMNA
SCHEMBL22862876 0.74 SMN1; SMN2 (0.38) SMN1; SMN2HTTUBE2NL3MBTL1GLA
SCHEMBL38653371 0.71 CSF1R (0.47) SMN1; SMN2HTTUBE2NL3MBTL1LMNA
SCHEMBL22862657 0.71 CSF1R (0.47) SMN1; SMN2HTTUBE2NL3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260132147-A1 BAX INHIBITORS AND USES THEREOF CASE WESTERN RESERVE UNIV (US) 2026-05-14 — — US disclosed
EP-3976009-A2 BAX INHIBITORS AND USES THEREOF Case Western Reserve University (US) 2022-04-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260132147-A1 BAX INHIBITORS AND USES THEREOF BAX, BCL2, BAK1 SMN1; SMN2 1412/4885HTT 3708/4885UBE2N 3303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback